Disruption of type 5 adenylyl cyclase gene preserves cardiac function against pressure overload

The sympathetic nervous system is designed to respond to stress. Adenylyl cyclase (AC) is the keystone of sympathetic transmission, yet its role in response to acute overload in the heart or in the pathogenesis of heart failure is controversial. We examined the effects of pressure overload, induced by thoracic aortic banding, in mice in which type 5 AC, a major cardiac AC isoform, was disrupted (AC5–/–). Left ventricular weight/tibial length ratio (LVW/TL) was not different between the WT and AC5–/– at baseline and increased progressively and similarly in both groups at 1 and 3 wk after aortic banding. However, LV ejection fraction (LVEF) fell in WT at 3 wk after banding (from 70 ± 2.8 to 57 ± 3.9%, P < 0.05), and this decrease was associated with LV dilatation, indicating incipient cardiac failure. In contrast, AC5–/– mice did not exhibit a fall in LVEF from 74 ± 2.2%. The number of apoptotic myocytes was similar at baseline, but it increased roughly 4-fold in WT at both 1 and 3 wk after banding, and significantly less, P < 0.05, in AC5–/–. Importantly, the increase in apoptosis occurred before the decline in LVEF in WT. The protective mechanism seems to involve Bcl-2, which was up-regulated significantly more in AC5–/– mice with pressure overload. Our findings suggest that limiting type 5 AC plays a protective role in response to pressure overload and the development of heart failure, potentially through limiting the incidence of myocardial apoptosis.

[1]  S. Vatner,et al.  β-Adrenergic receptor blockade arrests myocyte damage and preserves cardiac function in the transgenic Gsα mouse , 1999 .

[2]  M Feinleib,et al.  Role of blood pressure in the development of congestive heart failure. The Framingham study. , 1972, The New England journal of medicine.

[3]  S. Vatner,et al.  Downregulation of adenylylcyclase types V and VI mRNA levels in pacing-induced heart failure in dogs. , 1994, The Journal of clinical investigation.

[4]  M. Raynolds,et al.  Myocardial-directed overexpression of the human beta(1)-adrenergic receptor in transgenic mice. , 2000, Journal of molecular and cellular cardiology.

[5]  M. Gao,et al.  Adenylyl Cyclase Increases Survival in Cardiomyopathy , 2002, Circulation.

[6]  J. Cohn,et al.  The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group. , 1996, The New England journal of medicine.

[7]  L. Boxer,et al.  Induction of bcl-2 expression by phosphorylated CREB proteins during B-cell activation and rescue from apoptosis , 1996, Molecular and cellular biology.

[8]  W. Colucci,et al.  p38 Mitogen-activated Protein Kinase Pathway Protects Adult Rat Ventricular Myocytes against β-Adrenergic Receptor-stimulated Apoptosis , 2000, The Journal of Biological Chemistry.

[9]  T. Anzai,et al.  Adenylylcyclase increases responsiveness to catecholamine stimulation in transgenic mice. , 1999, Circulation.

[10]  S. Madersbacher,et al.  A low‐molecular‐weight fraction of human seminal plasma activates adenylyl cyclase and induces caspase 3‐independent apoptosis in prostatic epithelial cells by decreasing mitochondrial potential and Bcl‐2/Bax ratio , 2001, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[11]  S. Vatner,et al.  Adverse Effects of Chronic Endogenous Sympathetic Drive Induced by Cardiac Gsα Overexpression , 1996 .

[12]  S. Vatner,et al.  Cardiomyopathy induced by cardiac Gs alpha overexpression. , 1997, The American journal of physiology.

[13]  E. Olson,et al.  Cyclosporine attenuates pressure-overload hypertrophy in mice while enhancing susceptibility to decompensation and heart failure. , 1999, Circulation research.

[14]  J. Hanoune,et al.  Enhanced cardiac function in transgenic mice expressing a Ca(2+)-stimulated adenylyl cyclase. , 2000, Circulation research.

[15]  Y. Ishikawa,et al.  The adenylyl cyclases as integrators of transmembrane signal transduction. , 1997, Circulation research.

[16]  K. Adams,et al.  Carvedilol produces dose-related improvements in left ventricular function and survival in subjects with chronic heart failure. MOCHA Investigators. , 1996, Circulation.

[17]  M. Lohse,et al.  Progressive hypertrophy and heart failure in beta1-adrenergic receptor transgenic mice. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[18]  E. Olson,et al.  Dilated Cardiomyopathy and Sudden Death Resulting From Constitutive Activation of Protein Kinase A , 2001, Circulation research.

[19]  R. Virmani,et al.  Apoptosis in heart failure: release of cytochrome c from mitochondria and activation of caspase-3 in human cardiomyopathy. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[20]  S. Vatner,et al.  Is treating cardiac hypertrophy salutary or detrimental: the two faces of Janus. , 2003, American journal of physiology. Heart and circulatory physiology.

[21]  S. Vatner,et al.  beta-adrenergic receptor signaling: an acute compensatory adjustment-inappropriate for the chronic stress of heart failure? Insights from Gsalpha overexpression and other genetically engineered animal models. , 2000, Circulation research.

[22]  M. Gao,et al.  Cardiac-directed adenylyl cyclase expression improves heart function in murine cardiomyopathy. , 1999, Circulation.

[23]  B. Kobilka,et al.  Dual modulation of cell survival and cell death by beta(2)-adrenergic signaling in adult mouse cardiac myocytes. , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[24]  A. Dart,et al.  beta(2)-adrenergic receptor overexpression exacerbates development of heart failure after aortic stenosis. , 2000, Circulation.

[25]  G. Dorn,et al.  Altering the receptor-effector ratio by transgenic overexpression of type V adenylyl cyclase: enhanced basal catalytic activity and function without increased cardiomyocyte beta-adrenergic signalling. , 1999, Biochemistry.

[26]  S. Korsmeyer,et al.  Involvement of Microtubules in the Regulation of Bcl2 Phosphorylation and Apoptosis through Cyclic AMP-Dependent Protein Kinase , 1998, Molecular and Cellular Biology.

[27]  G. Dorn,et al.  Early and delayed consequences of beta(2)-adrenergic receptor overexpression in mouse hearts: critical role for expression level. , 2000, Circulation.

[28]  J. Hanoune,et al.  Tissue specificity and physiological relevance of various isoforms of adenylyl cyclase. , 2000, American journal of physiology. Renal physiology.

[29]  J. Hanoune,et al.  Type V, but not type VI, adenylyl cyclase mRNA accumulates in the rat heart during ontogenic development. Correlation with increased global adenylyl cyclase activity. , 1995, Journal of molecular and cellular cardiology.

[30]  J. Hoerter,et al.  Augmentation of cardiac contractility with no change in L‐type Ca2+ current in transgenic mice with a cardiac‐directed expression of the human adenylyl cyclase type 8 (AC8) , 2002, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[31]  S. Liggett,et al.  Transgenic replacement of type V adenylyl cyclase identifies a critical mechanism of β‐adrenergic receptor dysfunction in the Gαq overexpressing mouse , 1999 .

[32]  Y. Ishikawa,et al.  Changes in type VI adenylyl cyclase isoform expression correlate with a decreased capacity for cAMP generation in the aging ventricle. , 1994, Circulation research.

[33]  S. Vatner,et al.  Beta-adrenergic receptor-G protein-adenylyl cyclase signal transduction in the failing heart. , 1999, The American journal of cardiology.